يعرض 1 - 10 نتائج من 78 نتيجة بحث عن '"Oral Azacitidine"', وقت الاستعلام: 1.28s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

    المؤلفون: Farhad Ravandi, Gail J. Roboz, Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Dominik Selleslag, Pau Montesinos, Hamid Sayar, Maurizio Musso, Angela Figuera-Alvarez, Hana Safah, William Tse, Sang Kyun Sohn, Devendra Hiwase, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, Rochelle Bailey, Jianhua Zhong, C. L. Beach, Herve Dombret

    المصدر: Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-14 (2021)

    مصطلحات موضوعية: Oral azacitidine, CC-486, Safety, Maintenance, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

    وصف الملف: electronic resource

    العلاقة: https://doaj.org/toc/1756-8722Test

    الوصول الحر: https://doaj.org/article/643e4039c05b4d0693acd3685dcccc4bTest

    View record in DOAJ النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Additional file 1 of Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

    المؤلفون: Farhad Ravandi (11351696), Gail J. Roboz (10192006), Andrew H. Wei (11351699), Hartmut Döhner (276603), Christopher Pocock (11351702), Dominik Selleslag (4174144), Pau Montesinos (588135), Hamid Sayar (11351705), Maurizio Musso (1363815), Angela Figuera-Alvarez (11351708), Hana Safah (11351711), William Tse (216252), Sang Kyun Sohn (7019051), Devendra Hiwase (11351714), Timothy Chevassut (11351717), Francesca Pierdomenico (4878103), Ignazia La Torre (11351720), Barry Skikne (785629), Rochelle Bailey (11351723), Jianhua Zhong (11351726), C. L. Beach (11351729), Herve Dombret (11351732)

    مصطلحات موضوعية: Medicine, Cell Biology, Pharmacology, Cancer, Science Policy, Hematology, Oral azacitidine, CC-486, Safety, Maintenance

    العلاقة: https://figshare.com/articles/journal_contribution/Additional_file_1_of_Management_of_adverse_events_in_patients_with_acute_myeloid_leukemia_in_remission_receiving_oral_azacitidine_experience_from_the_phase_3_randomized_QUAZAR_AML-001_trial/16530023Test

    الإتاحة: https://doi.org/10.6084/m9.figshare.16530023.v1Test

    View record in BASE

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

    المؤلفون: Ravandi, Farhad, Roboz, Gail J., Wei, Andrew H., Döhner, Hartmut, Pocock, Christopher, Selleslag, Dominik, Montesinos, Pau, Sayar, Hamid, Musso, Maurizio, Figuera‑Alvarez, Angela, Safah, Hana, Tse, William, Sohn, Sang Kyun, Hiwase, Devendra, Chevassut, Timothy, Pierdomenico, Francesca, La Torre, Ignazia, Skikne, Barry, Bailey, Rochelle, Zhong, Jianhua, Beach, C. L., Dombret, Herve

    المساهمون: Medicine, School of Medicine

    المصدر: PMC

    مصطلحات موضوعية: Oral azacitidine, CC-486, Safety, Maintenance

    وصف الملف: application/pdf

    العلاقة: Journal of Hematology & Oncology; Ravandi F, Roboz GJ, Wei AH, et al. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. J Hematol Oncol. 2021;14(1):133. Published 2021 Aug 28. doi:10.1186/s13045-021-01142-x; https://hdl.handle.net/1805/39745Test

    الإتاحة: https://doi.org/10.1186/s13045-021-01142-xTest
    https://hdl.handle.net/1805/39745Test

    View record in BASE

    أضف إلى المفضلة
  4. 4
    Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

    المؤلفون: Jianhua Zhong, Hamid Sayar, Dominik Selleslag, Christopher Pocock, C.L. Beach, Farhad Ravandi, Rochelle Bailey, Pau Montesinos, Angela Figuera-Alvarez, Sang Kyun Sohn, Andrew H. Wei, Hervé Dombret, William Tse, Hartmut Döhner, Francesca Pierdomenico, Maurizio Musso, Gail J. Roboz, Timothy Chevassut, Hana Safah, Devendra K Hiwase, Ignazia La Torre, Barry S. Skikne

    المصدر: Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-14 (2021)
    JOURNAL OF HEMATOLOGY & ONCOLOGY
    r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
    instname
    Journal of Hematology & Oncology

    مصطلحات موضوعية: Male, Cancer Research, medicine.medical_specialty, Antimetabolites, Antineoplastic, Neutropenia, Gastrointestinal Diseases, Maintenance, Phases of clinical research, Administration, Oral, Placebo, Oral Azacitidine, Maintenance therapy, Internal medicine, medicine, Humans, Diseases of the blood and blood-forming organs, Adverse effect, Molecular Biology, RC254-282, Aged, Aged, 80 and over, Oral azacitidine, business.industry, Myelodysplastic syndromes, Research, Remission Induction, Disease Management, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Anemia, Hematology, Middle Aged, medicine.disease, Placebo Effect, Thrombocytopenia, Discontinuation, Leukemia, Myeloid, Acute, Oncology, Concomitant, Azacitidine, Female, Safety, RC633-647.5, business, CC-486

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e9e05abab8312fc9f61678ffcc1c4a0Test
    https://doaj.org/article/643e4039c05b4d0693acd3685dcccc4bTest


    أضف إلى المفضلة
  5. 5
    Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

    المؤلفون: Julio C. Chavez, James Drew, John P. Leonard, Erin Mulvey, Sonali M. Smith, Leandro Cerchietti, Nancy L. Bartlett, John L. Reagan, Jeffrey A. Jones, Ann S. LaCasce, Peter Martin, Maria Victoria Revuelta, Chengqing Wu

    المصدر: Blood. 139:1147-1159

    مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Vincristine, Maximum Tolerated Dose, Cyclophosphamide, Immunology, Azacitidine, Follicular lymphoma, Administration, Oral, Neutropenia, Biochemistry, Gastroenterology, Disease-Free Survival, Oral Azacitidine, Risk Factors, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Aged, Aged, 80 and over, business.industry, Cell Biology, Hematology, Middle Aged, medicine.disease, Survival Rate, Hypomethylating agent, Doxorubicin, Prednisone, Female, Lymphoma, Large B-Cell, Diffuse, Rituximab, business, Febrile neutropenia, Follow-Up Studies, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f681cae8547800b364ca87ee6ed83011Test
    https://doi.org/10.1182/blood.2021011679Test


    أضف إلى المفضلة
  6. 6
    Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial

    المؤلفون: Uwe M. Martens, Jun Ho Jang, Farhad Ravandi, Julia Braverman, Shien Guo, Ming Chung Wang, Jane L. Liesveld, C.L. Beach, Teresa Bernal, Barry S. Skikne, Christopher Pocock, Jiří Mayer, Peiwen Yu, Hartmut Döhner, Gail J. Roboz, Qian Dong, Ling Shi, Dominik Selleslag, Andrew H. Wei, Salem Abi Nehme, Ignazia La Torre, Hervé Dombret

    المصدر: Haematologica. 106:3240-3244

    مصطلحات موضوعية: Oncology, Health related quality of life, medicine.medical_specialty, business.industry, Internal medicine, medicine, MEDLINE, Myeloid leukemia, Hematology, Placebo, business, Oral Azacitidine

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::cc56742deef2ae04ca2a891cfa3f2060Test
    https://doi.org/10.3324/haematol.2021.279174Test


    أضف إلى المفضلة
  7. 7
    The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes

    المؤلفون: David Kipp, Andrew H. Wei

    المصدر: Future Oncology. 17:2563-2571

    مصطلحات موضوعية: Oncology, Antimetabolites, Antineoplastic, Cancer Research, medicine.medical_specialty, Biological Availability, Chronic myelomonocytic leukemia, Decitabine, Oral Azacitidine, 03 medical and health sciences, 0302 clinical medicine, Maintenance therapy, Internal medicine, medicine, Humans, Drug Approval, Uridine, Randomized Controlled Trials as Topic, business.industry, Myelodysplastic syndromes, Remission Induction, Myeloid leukemia, General Medicine, DNA Methylation, medicine.disease, Drug Combinations, Leukemia, Myeloid, Acute, Clinical Trials, Phase III as Topic, International Prognostic Scoring System, Myelodysplastic Syndromes, 030220 oncology & carcinogenesis, Cytidine Deaminase Inhibitor, Azacitidine, business, 030215 immunology, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd8c991ff5d3a7a9d274535f71615858Test
    https://doi.org/10.2217/fon-2020-1318Test


    أضف إلى المفضلة
  8. 8
    Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

    المؤلفون: Thai H. Ho, C.L. Beach, Eric Laille, Barry S. Skikne, Michael R. Savona, Kao Tai Tsai, Dale R. Shepard, Maen Abdelrahim, Mohammed M. Milhem, Hani M. Babiker, William Jeffery Edenfield, Joseph Aisner, Swaminathan P. Iyer

    المصدر: Cancer Chemotherapy and Pharmacology

    مصطلحات موضوعية: Pharmacology, Cancer Research, medicine.medical_specialty, FOOD EFFECT, Oral azacitidine, Adult patients, business.industry, Short Communication, Pharmacology toxicology, Cancer, Bioequivalence, Toxicology, medicine.disease, Oral Azacitidine, Bioavailability, Oncology, Pharmacokinetics, Internal medicine, medicine, Pharmacology (medical), business, CC-486

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eac474561c68318279391a8c405ec6a2Test
    https://doi.org/10.1007/s00280-020-04037-9Test


    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.

    المؤلفون: Roboz, Gail J, Montesinos, Pau, Selleslag, Dominik, Wei, Andrew, Jang, Jun-Ho, Falantes, Jose, Voso, Maria T, Sayar, Hamid, Porkka, Kimmo, Marlton, Paula, Almeida, Antonio, Mohan, Sanjay, Ravandi, Farhad, Garcia-Manero, Guillermo, Skikne, Barry, Kantarjian, Hagop

    مصطلحات موضوعية: CC-486, Phase III, acute myeloid leukemia, de novo, elderly, maintenance therapy, oral azacitidine, secondary, Administration, Oral, Antimetabolites, Antineoplastic, Azacitidine, Clinical Trials, Phase III as Topic, Humans, Leukemia, Myeloid, Acute, Maintenance Chemotherapy, Middle Aged, Randomized Controlled Trials as Topic

    وصف الملف: application/pdf

    العلاقة: http://hdl.handle.net/10668/9745Test; PMC5684733; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684733/pdfTest

    الإتاحة: https://doi.org/10.2217/fon.15.326Test
    http://hdl.handle.net/10668/9745Test
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684733/pdfTest

    View record in BASE

    أضف إلى المفضلة
  10. 10
    Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model

    المؤلفون: Mohammad Azab, Harold N. Keer, Michael R. Savona, Maria Pia Arrate, Londa Fuller, Aram Oganesian, Haley E. Ramsey, Agnieszka E. Gorska, Kelli L. Boyd

    المصدر: Targeted Oncology

    مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Myeloid, Azacitidine, Administration, Oral, Decitabine, Pharmacology, Oral Azacitidine, Mice, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols, medicine, Animals, Humans, Infusions, Parenteral, Pharmacology (medical), Original Research Article, Uridine, Venetoclax, business.industry, Myeloid leukemia, Haplorhini, Disease Models, Animal, stomatognathic diseases, Regimen, Treatment Outcome, 030104 developmental biology, medicine.anatomical_structure, Oncology, chemistry, 030220 oncology & carcinogenesis, Female, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::061a9fb59863d3e0c8119350a69a3138Test
    https://doi.org/10.1007/s11523-020-00709-xTest


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث